Since our results indicate that BCL-xL reduction by A-1331852 potentiates regorafenib activity and low MCL-1 levels expose A-1331852 anti-tumoral activity against HCC tumor cells, we focused our attention on BCL-xL and MCL-1 alterations exhibited by human HCC tumors. The gene discussed is BCL2L1; the disease is neoplasm.